Top Markets
#1 Black Phoenix Black Phoenix +828.22%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +26.74%
#3 Not in Employment, Education, or Training Not in Employment, Education, or Training +25.29%
#4 Bless Bless +21.01%
#5 SAFEcoin SAFEcoin +20.57%
#6 pipedog pipedog +20.53%
#7 Magma Finance Magma Finance +20.34%
#8 PondCoin PondCoin +20.03%
#9 Beam Beam +19.60%
#10 YFSX YFSX +16.01%
Coin of the day
Black Phoenix Black Phoenix
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Nanobiotix S.A. Nanobiotix S.A.

Nanobiotix S.A.

NANO
Rangering i aksjer #5950
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on... Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Aksjekurs
$45.79
Markedsverdi
$2.33B
Endring (1 dag)
11.43%
Endring (1 år)
408.10%
Land
FR
Handel Nanobiotix S.A. (NANO)

Kategori

Healthcare
Inntekter for Nanobiotix S.A. (NANO)
Inntekter i Aug 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til Nanobiotix S.A. er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Nanobiotix S.A. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH